Holen Sie sich die Stockscreener-App
9.06
1.09%
-0.10
Handel nachbörslich:
9.20
0.14
+1.55%
Schlusskurs vom Vortag:
$9.16
Offen:
$9.2
24-Stunden-Volumen:
2.60M
Relative Volume:
0.64
Marktkapitalisierung:
$1.97B
Einnahmen:
$61.10M
Nettoeinkommen (Verlust:
$-138.36M
KGV:
-6.7111
EPS:
-1.35
Netto-Cashflow:
$-90.59M
1W Leistung:
+1.68%
1M Leistung:
-15.25%
6M Leistung:
-27.37%
1J Leistung:
+21.53%
1-Tages-Spanne:
$8.92
$9.25
1-Wochen-Bereich:
$8.6331
$9.69
52-Wochen-Spanne:
$5.80
$16.44
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Firmenname
Ocular Therapeutix Inc
Sektor
Branche
Telefon
781-357-4000
Adresse
15 CROSBY DRIVE, BEDFORD, MA
Compare OCUL vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
9.06 | 1.99B | 61.10M | -138.36M | -90.59M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-15 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-04-08 | Eingeleitet | William Blair | Outperform |
| 2025-03-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-03-11 | Eingeleitet | Needham | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-20 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-05-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2024-02-09 | Eingeleitet | BofA Securities | Buy |
| 2023-04-21 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-08-10 | Fortgesetzt | Berenberg | Buy |
| 2021-08-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-11-13 | Bestätigt | Raymond James | Strong Buy |
| 2020-08-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-03 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | Herabstufung | Cowen | Outperform → Market Perform |
| 2019-05-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-21 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-11-15 | Eingeleitet | Raymond James | Strong Buy |
| 2018-09-07 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-10-24 | Eingeleitet | Guggenheim | Buy |
| 2017-07-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-07-12 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-06-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-11-15 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-08-11 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-02-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Ocular Therapeutix Inc Aktie (OCUL) Neueste Nachrichten
Ocular Therapeutix: Considering Their Phase 3 'Superiority' Trial's Prospect (NASDAQ:OCUL) - Seeking Alpha
Ocular Therapeutix Equity Grants Balance Growth Plans And Dilution Concerns - Yahoo Finance
Why It's Time To Keep A Close Eye On OCUL - RTTNews
Ocular Therapeutix (OCUL) Stock Analysis: A Biotech Gem With 171% Upside Potential - DirectorsTalk Interviews
Bearish Setup: Is Ocular Therapeutix Inc gaining market shareDay Trade & Daily Stock Trend Reports - baoquankhu1.vn
Ocular Therapeutix Faces Declining Sales and Profitability Amid Market Sentiment Shift - Markets Mojo
Aug Closing: Will Ocular Therapeutix Inc stock hit new highs in YEARMarket Sentiment Summary & Consistent Return Strategy Ideas - baoquankhu1.vn
Analysts Conflicted on These Healthcare Names: Illumina (ILMN) and Ocular Therapeutix (OCUL) - The Globe and Mail
Will Ocular Therapeutix Inc stock hit new highs in YEARWeekly Risk Summary & Safe Entry Point Identification - baoquankhu1.vn
Ocular Therapeutix (NASDAQ:OCUL) Raised to Hold at Wall Street Zen - MarketBeat
(OCUL) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
RBC Capital reiterates Outperform rating on Ocular Therapeutix stock By Investing.com - Investing.com Canada
Assessing Ocular Therapeutix (OCUL) Valuation After Recent Share Price Volatility - Sahm
Ocular Therapeutix Inc earnings beat by $0.03, revenue fell short of estimates - Investing.com South Africa
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Regulatory Turbulence Threatens Ocular Therapeutix: FDA Disruptions and Global Delays Raise Approval and Funding Risks - TipRanks
Ocular Therapeutix Reports Fourth Quarter and Full Year 2025 Financials, Provides Business Highlights - VisionMonday.com
Decoding Ocular Therapeutix Inc (OCUL): A Strategic SWOT Insight - GuruFocus
Ocular Therapeutix (NASDAQ:OCUL) Misses Q4 CY2025 Revenue Estimates - Finviz
Ocular Therapeutix's Recent Stock Weakness Presents Buying Opportunity, RBC Says - marketscreener.com
Ocular Therapeutix (NASDAQ:OCUL) Shares Up 8.8% on Better-Than-Expected Earnings - MarketBeat
Ocular Q4 Revenue Declines; Phase 3 Wet AMD Trial Data Expected Later This Month - Nasdaq
Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Ocular Therapeutix: Q4 Earnings Snapshot - kare11.com
Ocular Therapeutix Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - TradingView
Ocular Therapeutix: Fourth Quarter Earnings Overview - Bitget
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - The Manila Times
Earnings Beat: Is Ocular Therapeutix Inc stock heavily shorted2025 Momentum Check & Fast Momentum Entry Tips - baoquankhu1.vn
Ocular Therapeutix (NASDAQ:OCUL) COO Sells $51,538.90 in Stock - MarketBeat
Insider Selling: Ocular Therapeutix (NASDAQ:OCUL) COO Sells 5,455 Shares of Stock - MarketBeat
Notman, Ocular Therapeutix COO, sells $101,396 in stock By Investing.com - Investing.com Canada
Notman, Ocular Therapeutix COO, sells $101,396 in stock - Investing.com
Ocular Therapeutix Sees Unusually Large Options Volume (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix: Why SOL-1 Trial Outcome Is Likely Positive (NASDAQ:OCUL) - Seeking Alpha
Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) Institutional Investors Lost 16% Last Week but Have Benefitted From Longer-term Gains - 富途牛牛
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Ocular Therapeutix Leadership Shifts And Valuation Gap Draw Investor Focus - Sahm
Ocular Therapeutix (NASDAQ:OCUL) Share Price Crosses Below 200-Day Moving AverageHere's Why - MarketBeat
Is Ocular Therapeutix Inc. undervalued by DCF analysisJuly 2025 Spike Watch & Short-Term Trading Opportunity Alerts - Mfd.ru
A Look At Ocular Therapeutix (OCUL) Valuation After Mixed Earnings And New Executive Appointments - Sahm
Is Ocular Therapeutix’s (OCUL) New Commercial Hire Quietly Reframing Its Long‑Term Strategy? - Yahoo Finance
RSI Alert: Ocular Therapeutix (OCUL) Now Oversold - Nasdaq
Ocular Therapeutix, Inc. (OCUL) Stock Analysis: Biotechnology Innovator with 122% Upside Potential - DirectorsTalk Interviews
Responsive Playbooks and the OCUL Inflection - Stock Traders Daily
A Look Back at Pharmaceuticals Stocks’ Q3 Earnings: Ocular Therapeutix (NASDAQ:OCUL) Vs The Rest Of The Pack - Yahoo Finance
Decliners Report: Is Ocular Therapeutix Inc undervalued by DCF analysisJuly 2025 Sentiment & Detailed Earnings Play Alerts - baoquankhu1.vn
Corticosteroids Market Report 2026 - GlobeNewswire Inc.
Bearish Setup: Whats Ocular Therapeutix Incs historical return2025 Historical Comparison & Precise Entry and Exit Recommendations - baoquankhu1.vn
Ocular Therapeutix appoints Jason Robins interim CFO - The Globe and Mail
Ocular Therapeutix (NASDAQ:OCUL) Shares Down 5.9%What's Next? - MarketBeat
Finanzdaten der Ocular Therapeutix Inc-Aktie (OCUL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):